Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Public comment period · §2

Draft monograph: GHRP-2 — submissions

The 7 submissions received, published in full with declared interests and secretariat responses.

Document identifier
CEI-CP-051/2
Series
Public comment period
Version
1.0
Published
30 Mar 2025
Last reviewed
30 Mar 2025
Next review
30 Mar 2026
Identifier
10.71829/cei.cp.51
Certainty
Not rated
Cycle
2025 Q1
Window
10 Jan 2025 – 21 Feb 2025
Status
Closed
Submissions
7

§2Submissions and responses

7 submissions were received. Each is published in full below with its declared interest, the secretariat response and the disposition. The Institute publishes submissions it did not accept in the same form as those it did.

Gaspard Kettlewell, BPharm, PhD National pharmacovigilance centre
DRAFT-GHRP-2-MONOG/002 received 20 Jan 2025

Declared interests should appear on the document rather than on a separate page

The draft links to a central conflicts register. The respondent argues that a reader assessing whether to rely on a particular document should not have to leave it to find out who assessed it and what they declared.

The respondent proposes that the interests of every named contributor to a document be printed on that document.

Declared interest. Is a member of the Institute's external reviewer register but did not review the document under consultation.
Secretariat responseNoted, no amendment12 Mar 2025

The secretariat notes this submission and records that the draft already provides for it, which the respondent could reasonably have missed because the provision sits in an appendix.

Every document carries the declared interests of its named contributors in its front matter, and the central register exists so that a reader can see a person across all documents rather than one at a time. No amendment arises; the provision has been moved from the appendix into the body of the methodology document so that it is findable.

Dr Hyacinth Drakeford-Amadi, PhD (Toxicology) Health-technology assessment agency
DRAFT-GHRP-2-MONOG/003 received 03 Feb 2025

Registered trials that never reported are absent from the monograph

The respondent states that the trial list appears to be drawn from published reports, and that registered trials which completed without a report are therefore invisible. The proportion of a programme that never reported is itself a finding about the evidence base.

The respondent proposes that every registered trial of the compound be listed, with its reporting status, whether or not a report exists.

Declared interest. Has used a compound in the class under assessment under prescription. Declared at the Institute's request; the Institute regards a lived-experience declaration as an interest and not as a disqualification.
Secretariat responseAccepted05 Mar 2025

The secretariat accepts this submission. A trial list built from publications reproduces publication bias in the shape of the document.

The trial list now includes every registered trial the Institute identified, with its reporting status stated, and the monograph reports the proportion of registered trials for which no result has been posted or published.

Adaeze Underhill-Okafor, PhD (Medicinal Chemistry) University department of public health
DRAFT-GHRP-2-MONOG/007 received 03 Feb 2025

The analytical section is longer than the clinical assessment it accompanies

The respondent, an academic pharmacologist, states that the analytical section occupies more of the monograph than the assessment of clinical effect, and that the proportions imply the Institute considers the analytical question the more important one.

The respondent proposes that the analytical material be moved to the standards series and referenced rather than reproduced.

Declared interest. Is a trustee of a patient organisation that has received a restricted educational grant from a manufacturer in the class under assessment.
Secretariat responseAccepted in part13 Mar 2025

The secretariat accepts this submission in part. The general analytical material is moved to the standards series and referenced. The compound-specific material stays, because a reader holding a certificate for this compound needs to know what that certificate does and does not establish for this compound.

The analytical section is reduced to compound-specific content and cross-references the relevant standards for the general procedure, which shortens it substantially without removing what is not available elsewhere.

Dr Nikolai Yeovil-Bakare, PhD (Chemistry), MRSC University department of pharmacy practice
DRAFT-GHRP-2-MONOG/006 received 06 Feb 2025

The certainty rating for the principal assessed outcome cannot be traced to the contributing trials

The draft states a certainty rating for the principal assessed outcome and lists the contributing trials, but does not state which domain drove the downgrade. A reader who disagrees with the rating cannot tell whether the disagreement concerns risk of bias, imprecision, indirectness or inconsistency.

The respondent proposes that each rating carry its downgrade reasons explicitly, in the same row as the rating, so that a reader can accept the evidence assessment while disputing a single domain judgement.

Declared interest. No financial interest. Has published a systematic review reaching a different conclusion from the draft, which the respondent declares as a non-financial interest.
Secretariat responseAccepted05 Mar 2025

The secretariat accepts this submission. A rating without its reasoning is an assertion, and the draft asserted rather than showed.

Each assessed outcome now carries its downgrade domains in the summary-of-findings row, with a short statement of the judgement made in each, so that the rating can be checked domain by domain against the contributing trials.

Dr Evander Whitmarsh-Obi, MD, MSc Community pharmacy practice, doctoral candidate
DRAFT-GHRP-2-MONOG/005 received 12 Feb 2025

Doses are expressed in units that differ between sections

The draft expresses dose in milligrams in one section and in micrograms per kilogram in another, drawn from different sources without conversion. The respondent, a hospital pharmacist, states that this is the shape of error that reaches a patient.

The respondent proposes a single unit throughout, with the source unit retained in parentheses where a conversion was performed.

Declared interest. Employed by a national competent authority. This submission is made in a personal capacity and does not represent the position of that authority.
Secretariat responseAccepted19 Mar 2025

The secretariat accepts this submission. The inconsistency was inherited from the sources and should have been resolved in drafting.

A single dose unit is now used throughout each monograph, with the source unit retained in parentheses wherever a conversion was applied, and every conversion is stated rather than performed silently.

Valentin Tollemache, PharmD, PhD University teaching hospital, department of endocrinology
DRAFT-GHRP-2-MONOG/001 received 14 Feb 2025

A sortable table implies a comparison the underlying data do not support

The draft presents a sortable table whose columns are drawn from sources of differing quality. The respondent states that sorting on such a column produces an ordering that looks like a ranking and is not one.

The respondent proposes that sorting be disabled on any column whose values are not commensurable.

Declared interest. Has received consultancy fees from a supplier named in the Institute's supplier assessment set within the preceding two years.
Secretariat responseNoted, no amendment25 Mar 2025

The secretariat notes this submission and records that the point is correct in principle.

No amendment arises here because every sortable table in the document set already carries a standing statement above it that the ordering is not a ranking and that the values in each column are commensurable only where the column header says so. The proposal to disable sorting was considered and not adopted, because a reader who cannot sort a table generally sorts it elsewhere and without the statement.

Professor Bartolomeu Nkosi-Lindegaard, PhD Professor of Regulatory Science
DRAFT-GHRP-2-MONOG/004 received 20 Feb 2025

The monograph should not describe how the compound is supplied outside a regulated route

The respondent states that describing presentations observed in unregulated supply risks being read as a guide to obtaining them, and asks that the material be removed.

The respondent accepts that the information is accurate and objects to its presence rather than to its content.

Declared interest. Is an employee of a marketing-authorisation holder for a compound named in the draft. This submission is made on behalf of that company and is identified as an industry submission throughout.
Secretariat responseNoted, no amendment12 Mar 2025

The secretariat notes this submission and records the concern as a real one that the draft had already considered.

No amendment arises. The monograph describes what is supplied and names no supplier, price or route of acquisition, and it carries the standing statement that the Institute assesses evidence and does not recommend use. Describing a presentation a reader may already hold is the condition of being useful to that reader.

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.